Ellen M. Apperloo

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Ellen M. Apperloo, José Luis Górriz, María José Soler et al. · Nature Medicine · 2024 · 97 citations · Full text

Medicine, Nephrology, Pharmacology +11

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies et al. · Diabetes Care · 2023 · 90 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials

Ellen M. Apperloo, Katherine R. Tuttle, Imre Pávó et al. · Diabetes Care · 2025 · 44 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study

Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs et al. · Diabetes Obesity and Metabolism · 2023 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6

Ellen M. Apperloo, David Z.I. Cherney, Anja Birk Kuhlman et al. · Nephrology Dialysis Transplantation · 2024 · 18 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +17